Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Results of Operations and Financial Condition

Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

On March 14, 2019, Novelion Therapeutics Inc. (the Company) announced its financial results for the quarter and year ended December 31, 2018. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
EX-99.1 2 a12312018earningsreleaseex.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Novelion Therapeutics Reports Fourth Quarter and Full Year 2018Financial Results–Company achieves FY 2018 total net revenues of $130.4 million–FY 2018 operating expenses reduced by $27.2 million,…
To view the full exhibit click here

Story continues below

About Novelion Therapeutics Inc. (NASDAQ:NVLN)

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

An ad to help with our costs